united american securities inc. d b a uas asset management decreased its position in Johnson & Johnson (NYSE:JNJ) by 1.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,765 shares of the company’s stock after selling 2,050 shares during the period. Johnson & Johnson accounts for 9.5% of united american securities inc. d b a uas asset management’s holdings, making the stock its 3rd largest position. united american securities inc. d b a uas asset management’s holdings in Johnson & Johnson were worth $13,793,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in JNJ. Emerald Acquisition Ltd. purchased a new position in shares of Johnson & Johnson during the second quarter worth $805,455,000. Vanguard Group Inc. raised its position in shares of Johnson & Johnson by 2.2% in the second quarter. Vanguard Group Inc. now owns 184,512,652 shares of the company’s stock worth $22,381,384,000 after buying an additional 3,924,090 shares during the period. Tesco Pension Investment Ltd purchased a new position in shares of Johnson & Johnson during the third quarter worth $148,524,000. APG Asset Management N.V. raised its position in shares of Johnson & Johnson by 17.7% in the third quarter. APG Asset Management N.V. now owns 7,224,544 shares of the company’s stock worth $853,435,000 after buying an additional 1,086,500 shares during the period. Finally, Fundsmith LLP raised its position in shares of Johnson & Johnson by 24.1% in the second quarter. Fundsmith LLP now owns 3,704,693 shares of the company’s stock worth $449,379,000 after buying an additional 719,532 shares during the period. Institutional investors own 65.37% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) opened at 115.24 on Friday. Johnson & Johnson has a 12-month low of $101.65 and a 12-month high of $126.07. The firm has a market cap of $313.51 billion, a P/E ratio of 19.43 and a beta of 0.74. The company’s 50 day moving average price is $114.45 and its 200 day moving average price is $117.02.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 24th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.56 by $0.02. The firm had revenue of $18.10 billion for the quarter, compared to the consensus estimate of $18.28 billion. Johnson & Johnson had a return on equity of 25.61% and a net margin of 22.78%. The business’s quarterly revenue was up 1.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.44 earnings per share. Equities research analysts forecast that Johnson & Johnson will post $7.04 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 14th. Shareholders of record on Tuesday, February 28th will be given a dividend of $0.80 per share. The ex-dividend date of this dividend is Friday, February 24th. This represents a $3.20 annualized dividend and a dividend yield of 2.78%. Johnson & Johnson’s dividend payout ratio is currently 54.42%.
ILLEGAL ACTIVITY NOTICE: “united american securities inc. d b a uas asset management Has $13,793,000 Stake in Johnson & Johnson (JNJ)” was reported by sleekmoney and is the sole property of of sleekmoney. If you are viewing this report on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at http://sleekmoney.com/united-american-securities-inc-d-b-a-uas-asset-management-has-13793000-stake-in-johnson-johnson-jnj/1656506.html.
JNJ has been the topic of a number of recent research reports. Vetr lowered Johnson & Johnson from a “buy” rating to a “hold” rating and set a $117.54 target price on the stock. in a research note on Monday, November 7th. RBC Capital Markets set a $133.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research note on Wednesday, November 9th. Zacks Investment Research lowered Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Tuesday, January 3rd. Barclays PLC lowered Johnson & Johnson from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $130.00 to $125.00 in a research note on Tuesday, November 29th. They noted that the move was a valuation call. Finally, Bank of America Corporation restated a “hold” rating and set a $126.00 price objective on shares of Johnson & Johnson in a research note on Monday, November 28th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and eight have assigned a buy rating to the stock. Johnson & Johnson has a consensus rating of “Hold” and a consensus price target of $122.92.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/united-american-securities-inc-d-b-a-uas-asset-management-has-13793000-stake-in-johnson-johnson-jnj/1656506.html
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.